Last $0.57 USD
Change Today 0.0001 / 0.02%
Volume 31.7K
GENE On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

genetic tech ltd-sp adr (GENE) Snapshot

Open
$0.60
Previous Close
$0.57
Day High
$0.60
Day Low
$0.56
52 Week High
10/1/13 - $2.49
52 Week Low
09/15/14 - $0.50
Market Cap
12.7M
Average Volume 10 Days
80.6K
EPS TTM
--
Shares Outstanding
22.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENETIC TECH LTD-SP ADR (GENE)

genetic tech ltd-sp adr (GENE) Related Bloomberg News

View More Bloomberg News

genetic tech ltd-sp adr (GENE) Related Businessweek News

No Related Businessweek News Found

genetic tech ltd-sp adr (GENE) Details

Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of DNA based genetic tests for cancer predisposition, including breast cancer, ovarian cancer, bowel cancer, and uterine cancer; neurogenetic diagnostic assays; and gene testing for gene related disorders. The company also provides DNA based tests comprising antenatal DNA testing, deceased estate DNA testing, DNA profiling, grandparent DNA testing, immigration DNA testing, legal paternity DNA testing, non-legal paternity DNA testing, sibling DNA testing, twins DNA testing, and Y-chromosome DNA testing services to determine parentage or relatedness. In addition, it offers animals’ tests consisting of disease testing, breed identification, coat color, and animal forensic DNA testing. Further, the company is involved in the out-licensing of its non-coding technology; and research and development activities in the field of genetics and related areas. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Founded in 1987

genetic tech ltd-sp adr (GENE) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$223.1K
Senior Vice President Sales & Marketing - Phe...
Total Annual Compensation: A$222.0K
Scientific Director
Total Annual Compensation: A$114.1K
Compensation as of Fiscal Year 2013.

genetic tech ltd-sp adr (GENE) Key Developments

Genetic Technologies Limited Announces Appointment of Non-Executive Directors

Genetic Technologies Limited announced that Mr. David Carter and Dr. Lindsay Wakefield have been appointed as Non-Executive Directors of the company on ‘casual appointment’, in that the new appointees will then be required to submit themselves for re-election at the upcoming AGM, as per article 19.4 of the company's Constitution. David is currently a director of Thorn Group Limited, Glutagen Pty Ltd; and In:Capital Pty Ltd. Dr. Wakefield continues as Managing Director of STS and has been a keen Biotech investor for past 20 years, often at a mezzanine level.

Genetic Technologies Limited Plans for the Restructure and Realignment of Group Activities

Genetic Technologies Limited announced that it plans for the restructure and realignment of group activities. These changes will enable the company to focus its strategy on the US molecular diagnostics market and commercialisation of the company's lead breast cancer risk test BREVAGenTM. The restructure and realignment of group activities follows a recent review of operations by the company aimed at supporting the company's US MDx strategy. The core plans approved by the board include: the sale /divestment of non-core assets; the realignment of internal cost structures through a disciplined approach to cost management and capital allocation being driven by the recently appointed CFO; a board restructure, including the appointment of new directors, to support and enhance company's focus on the US MDx market; and a proposed company name change to represent a MDx focus. The plans being implemented are targeted for completion over the next quarter, and are expected to provide investors with a focused MDx company and refined US commercialisation strategy for BREVAGen, with a significantly reduced operating cost base.

Genetic Technologies Limited Reports Consolidated Earnings Results for the Year Ended June 30, 2014

Genetic Technologies Limited reported consolidated earnings results for the year ended June 30, 2014. For the year, the company reported loss from continuing operations before income tax expense of $10,134,469, loss attributable to owners of the company of $10,125,197 or 1.76 cents per basic and diluted share on revenue from continuing operations ­ genetic testing services of $4,564,280 against loss from continuing operations before income tax expense of $9,349,483, loss of $9,349,483, loss attributable to owners of the company of $9,298,367 or 1.97 cents per basic and diluted share on revenue from continuing operations ­ genetic testing services of $3,377,183 for the same period a year ago. Net cash flows used in operating activities of $10,987,088 against $7,516,779 for the same period a year ago. Purchases of plant and equipment were $47,917 against $53,611 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENE:US $0.57 USD 0.0001

GENE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $56.98 USD -0.17
Bristol-Myers Squibb Co $51.18 USD -0.53
Pfizer Inc $29.57 USD -0.20
Sonic Healthcare Ltd A$17.61 AUD +0.07
View Industry Companies
 

Industry Analysis

GENE

Industry Average

Valuation GENE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECH LTD-SP ADR, please visit www.gtglabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.